Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Saved in:
| Title: | Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. |
|---|---|
| Authors: | Woyach, Jennifer1 (AUTHOR), Tedeschi, Alessandra2 (AUTHOR), Munir, Talha3 (AUTHOR), Siddiqi, Tanya4 (AUTHOR), Hillmen, Peter5 (AUTHOR), Byrd, John C.1 (AUTHOR), Ghia, Paolo6 (AUTHOR), Mulligan, Stephen P.7 (AUTHOR), Dai, Sandra8 (AUTHOR), Amaya-Chanaga, Carlos I.9 (AUTHOR), Dean, James P.10 (AUTHOR), O'Brien, Susan M.11 (AUTHOR), Barr, Paul M.12 (AUTHOR) |
| Source: | Leukemia & Lymphoma. Dec 2021, Vol. 62 Issue 13, p3278-3282. 5p. |
| Database: | Academic Search Ultimate |
| ISSN: | 10428194 |
|---|---|
| DOI: | 10.1080/10428194.2021.1957871 |
